Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema.
Humans
Receptors, Vascular Endothelial Growth Factor
/ administration & dosage
Recombinant Fusion Proteins
/ administration & dosage
Female
Male
Retrospective Studies
Macular Edema
/ drug therapy
Diabetic Retinopathy
/ drug therapy
Intravitreal Injections
Visual Acuity
Middle Aged
Angiogenesis Inhibitors
/ administration & dosage
Tomography, Optical Coherence
/ methods
Follow-Up Studies
Aged
Treatment Outcome
Drug Substitution
/ methods
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Aflibercept
Diabetic macular edema
Faricimab
Switch
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
25
03
2024
accepted:
16
06
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
25
6
2024
Statut:
epublish
Résumé
To assess the effectiveness of a switch to faricimab in individuals affected by DME and previously treated with aflibercept. In this retrospective, single-center study, DME patients previously treated with at least 3 injections of aflibercept then switched to faricimab were enrolled. Best corrected visual acuity (BCVA) and central subfield thickness (CST) were recorded at baseline, at the time of the switch and at 6 months follow-up. At transition to faricimab, patients were categorized as "good visual responders" (≥ 5 letters from baseline) or "poor visual responders" (< 5 letters), and as "good anatomical responders" (any reduction in edema compared to baseline) or "poor anatomical responders" (no reduction or worsening of edema). Changes in BCVA and CST were recorded at 6 months after the switch to faricimab. 100 eyes of 100 patients (61 female, 61%) were switched to faricimab after a mean of 6.8 ± 3.3 aflibercept injections. At the 6 months follow-up, only "poor visual responders" (N = 62) demonstrated a meaningful increase in BCVA (Δswitch-6M = + 5 letters; P = 0.007), coupled with a reduction in CST (Δswitch-6M = - 67.9 µm; P = 0.004); participants with "poor anatomical response" upon transitioning exhibited a significant functional gain (Δswitch-6M = + 4.5 letters; p = 0.05) but limited CST enhancements (Δswitch-6M = - 95.1 µm; p = 0.05). Faricimab shows a positive impact on anatomical and functional metrics in DME cases refractory to aflibercept.
Identifiants
pubmed: 38916818
doi: 10.1007/s10792-024-03226-2
pii: 10.1007/s10792-024-03226-2
doi:
Substances chimiques
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Recombinant Fusion Proteins
0
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
275Informations de copyright
© 2024. The Author(s).
Références
Nguyen QD, Brown DM, Marcus DM et al (2012) RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801
doi: 10.1016/j.ophtha.2011.12.039
pubmed: 22330964
Brown DM, Schmidt-Erfurth U, Do DV et al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122(10):2044–2052
doi: 10.1016/j.ophtha.2015.06.017
pubmed: 26198808
Rajendram R, Fraser-Bell S, Kaines A et al (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130(8):972–979
doi: 10.1001/archophthalmol.2012.393
pubmed: 22491395
Wu L, Martínez-Castellanos MA, Quiroz-Mercado H et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246(1):81–87
doi: 10.1007/s00417-007-0660-z
pubmed: 17674014
Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW et al (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114(10):1860–1867
doi: 10.1016/j.ophtha.2007.05.062
Wells JA, Glassman AR, Ayala AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203
doi: 10.1056/NEJMoa1414264
pubmed: 25692915
Bressler NM, Beaulieu WT, Glassman AR et al (2018) Diabetic retinopathy clinical research network. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136(3):257–269
doi: 10.1001/jamaophthalmol.2017.6565
pubmed: 29392288
pmcid: 5885906
Ciulla TA, Pollack JS, Williams DF (2021) Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol 105(2):216–221
doi: 10.1136/bjophthalmol-2020-315933
pubmed: 32265201
Shimura M, Kitano S, Muramatsu D et al (2020) Japan Clinical Retina Study (J-CREST) group. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study. Br J Ophthalmol 104(9):1209–1215
pubmed: 31784500
Mira F, Paulo M, Henriques F, Figueira J (2017) Switch to aflibercept in diabetic macular edema patients unresponsive to previous anti-VEGF therapy. J Ophthalmol 2017:5632634
doi: 10.1155/2017/5632634
pubmed: 28348885
pmcid: 5350533
Klein KA, Cleary TS, Reichel E (2017) Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. Int J Retina Vitreous 3(3):16
doi: 10.1186/s40942-017-0064-0
pubmed: 28373914
pmcid: 5376679
Chen YY, Chang PY, Wang JK (2017) Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab: analysis of response to aflibercept. Asia-Pac J Ophthalmol 6(3):250–255
Konidaris VE, Tsaousis KT, Al-Hubeshy Z, Pieri K, Deane J, Empeslidis T (2017) Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema. Eye (Lond) 31(11):1629–1630
doi: 10.1038/eye.2017.122
pubmed: 28622326
Demircan A, Alkin Z, Yesilkaya C, Demir G, Kemer B (2018) Comparison of intravitreal aflibercept and ranibizumab following initial treatment with ranibizumab in persistent diabetic macular edema. J Ophthalmol 19:4171628
Wood EH, Karth PA, Moshfeghi DM, Leng T (2015) Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab. Ophthalmic Surg Lasers Imaging Retina 46(9):950–954
doi: 10.3928/23258160-20151008-08
pubmed: 26469235
Shah CP, Heier JS (2016) Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retina 47(9):836–839
doi: 10.3928/23258160-20160901-06
pubmed: 27631479
Rahimy E, Shahlaee A, Khan MA, Ying G-S, Maguire JI, Ho AC et al (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 164:118-127.e2
doi: 10.1016/j.ajo.2015.12.030
pubmed: 26748058
Sahni J, Patel SS, Dugel PU et al (2019) Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology 126(8):1155–1170
doi: 10.1016/j.ophtha.2019.03.023
pubmed: 30905643
Wykoff C, Abreu F, Adamis AP et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399:741–755
doi: 10.1016/S0140-6736(22)00018-6
pubmed: 35085503
Lim RH, Gupta B, Simcock P (2017) Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab. Int J Ophthalmol 10(3):423–426
pubmed: 28393034
pmcid: 5360778
Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255(6):1133–1140
doi: 10.1007/s00417-017-3624-y
pubmed: 28238195
Rahimy E, Shahlaee A, Khan MA et al (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 164:118–27.e2
doi: 10.1016/j.ajo.2015.12.030
pubmed: 26748058
Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2):171–185
doi: 10.1007/s10456-011-9249-6
pubmed: 22302382
pmcid: 3338918
Nguyen QD, De Falco S, Behar-Cohen F et al (2018) Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol 96(1):e1–e9
doi: 10.1111/aos.13325
pubmed: 27874278
Wykoff CC, Ou WC, Khurana RN, Brown DM, Lloyd Clark W, Boyer DS (2018) Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol 102(5):631–636
doi: 10.1136/bjophthalmol-2017-310941
pubmed: 28814412
Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29(6):723–731
doi: 10.1097/IAE.0b013e3181a2c1c3
pubmed: 19516114
pmcid: 2770842
Durrani AF, Momenaei B, Wakabayashi T et al (2023) Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema. Br J Ophthalmol 12:bjo-2023-324394. https://doi.org/10.1136/bjo-2023-324394
doi: 10.1136/bjo-2023-324394
Rush RB, Rush SW (2022) Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol 24(16):2797–2801
doi: 10.2147/OPTH.S381503
Bressler NM, Beaulieu WT, Maguire MG et al (2018) Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. Am J Ophthalmol 195:93–100
doi: 10.1016/j.ajo.2018.07.030
pubmed: 30077569
pmcid: 6648655